• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

ESC: On Second Go-Round, MERLIN Finds Arrhythmia Magic in Ranolazine

Article

VIENNA -- The anti-anginal drug ranolazine (Ranexa) may reduce episodes of ventricular tachycardia and supraventricular tachycardia, researchers here reported.

VIENNA, Sept. 6 -- The anti-anginal drug ranolazine (Ranexa) may reduce episodes of ventricular tachycardia and supraventricular tachycardia, researchers reported here.

The potential benefit was detected in a pre-specified analysis of Holter monitor data from MERLIN-TIMI 36 -- a failed trial of ranolazine for treatment of acute coronary syndrome.

Yet the analysis showed that ranolazine reduced the number of ventricular tachycardia episodes by 37% (P

Related Videos
Related Content
Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection / image courtesy of University of Oxford

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection

Grace Halsey
April 21st 2025
Article

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

Site Logo

Women and Heart Disease: Incidence, Prevalence, Progress, and the Future

C Noel Bairey Merz, MD;Payal Kohli, MD
April 6th 2013
Podcast

Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women

Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose

Sydney Jennings
September 26th 2024
Article

Your daily dose of the clinical news you may have missed.

The Great Beta-Blocker Debate: The Pros and Cons

The Great Beta-Blocker Debate: The Pros and Cons

Gregory W. Rutecki, MD;Bradley Wright, PharmD
December 12th 2012
Podcast

Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose

Sydney Jennings
May 2nd 2024
Article

Your daily dose of the clinical news you may have missed.

New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought / Image credit: ©Horacio Selva/AdobeStock

New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought

Sydney Jennings
April 23rd 2024
Article

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

© 2025 MJH Life Sciences

All rights reserved.